[1] Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery[J]. Eur J Pharm Sci, 2001, 14(2):101-114.
[2] Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery[J]. Adv Drug Deliv Rev, 2011, 63(6):470-491.
[3] Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis[J]. Chem Phys Lipids, 2012, 165(4):454-461.
[4] Bachhav YG, Mondon K, Kalia YN, et al. Novel micelle formulations to increase cutaneous bioavailability of azole antifungals[J]. J Control Release, 2011, 153(2):126-132.
[5] Vijayan V, Reddy KR, Sakthivel S, et al. Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs:in vitro and in vivo studies[J]. Colloids Surf B Biointerfaces, 2013, 1(111):150-155.
[6] Agrawal U, Mehra NK, Gupta U et al. Hyperbranched dendritic nano-carriers for topical delivery of dithranol[J]. J Drug Target,2013, 21(5):497-506.
[7] Chen Y, Wang M, Fang L. Biomaterials as novel penetration enhancers for transdermal and dermal drug delivery systems[J]. Drug Deliv, 2013, 20(5):199-209.
[8] Rancan F, Papakostas D, Hadam S, et al. Investigation of polylactic acid(PLA) nanoparticles as drug delivery systems for local dermatotherapy[J]. Pharm Res, 2009, 26(8):2027-2036.
[9] Shah PP, Desai PR, Channer D, et al. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers[J]. J Controlled Release, 2012, 161(3):735-745.
[10] Shah PP, Desai PR, Patel AR, et al. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs[J]. Biomaterials, 2012, 33(5):1607-1617.
[11] Yang Y, Sunoqrot S, Stowell C, et al. Effect of size, surface charges, and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration[J]. Biomacromolecules,2012, 13(7):2154-2162.
[12] O'Leary J, Muggia FM. Camptothecins:a review of their development and schedules of administration[J]. Eur J Cancer, 1998,34(10):1500-1508.
[13] Min KH, Park K, Kim YS, et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy[J]. J Control Release,2008, 127(3):208-218.
[14] Andrew J. Jennifer K. Carmen J, et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors[J]. Drug Deliv Transl Res,2011,1(1):34-42.
[15] Castillo PM, de la Mata M, Casula MF, et al. PEGylated versus non-PEGylated magnetic nanoparticles as camptothecin delivery system[J]. Beilstein J Nanotechnol, 2014, 5:1312-1319.
[16] Zhang L, Hu Y, Jiang X, et al. Camptothecin derivative-loaded poly(caprolactone-co-lactide)-b-PEG-b-poly(caprolactone-co-lactide) nanoparticles and their biodistribution in mice[J]. J Control Release, 2004, 96(1):135-148.
[17] Botella P, Abasolo I, Fern ndez Y, et al. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation[J].J Control Release,2011,156(2):246-257.